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Abstract Indexes PRx and Mx have been formerly
introduced to assess cerebral autoregulation and have been
shown to be associated with 3-month clinical outcome. In a
mixed cohort of neurocritical care patients, we retrospec-
tively investigated the impact of selected clinical charac-
teristics on this association. Forty-one patients (18–77
years) with severe traumatic (TBI, N = 20) and non-trau-
matic (N = 21) brain injuries were studied. Cerebral blood
flow velocity, arterial blood pressure and intracranial
pressure were repeatedly recorded during 1-h periods.
Calculated PRx and Mx were correlated with 3-month
clinical outcome score of modified Rankin Scale (mRS) in
different subgroups with specific clinical characteristics.
Both PRx and Mx correlated significantly with outcome
(PRx: r = 0.38, p\ 0.05; AUC = 0.64, n.s./Mx: r = 0.48,
p\ 0.005; AUC = 0.80, p\ 0.005) in the overall group,
and in patients with hemicraniectomy (N = 17; PRx:
r = 0.73, p\ 0.001; AUC = 0.89, p\ 0.01/Mx: r =
0.69, p\ 0.005; AUC = 0.87, p\ 0.05). Mx, not PRx,
correlated significantly with mRS in patients with heart
failure (N = 17; r = 0.69, p\ 0.005; AUC = 0.92,
p\ 0.005), and in non-traumatic patients (r = 0.49,
p\ 0.05; AUC = 0.79, p\ 0.05). PRx, not Mx, corre-
lated significantly with mRS in TBI patients (r = 0.63,
p\ 0.01; AUC = 0.89, p\ 0.01). Both indexes did not
correlate with mRS in diabetes patients (N = 15), PRx
failed in hypocapnic patients (N = 26). Both PRx and Mx
were significantly associated with 3-month clinical out-
come, even in patients with hemicraniectomy. PRx was
more appropriate for TBI patients, while Mx was better
suited for non-traumatic patients and patients with heart
failure. Prognostic values of indexes were affected by
diabetes (both Mx and PRx) and hypocapnia (PRx only).
Keywords Cerebral autoregulation  Cerebrovascular
pressure reactivity  Modified Rankin Scale  Cerebral
blood flow  Traumatic brain injury  Stroke
1 Introduction
The purpose of cerebral autoregulation (CA) is to keep
cerebral blood flow (CBF) constant during variations of
cerebral perfusion pressure (CPP). A pressure reactivity
index PRx and a CBF related index Mx have been formerly
introduced to assess CA [1–5] in patients with acute severe
cerebral diseases. Although the pathophysiologic basis of
both indexes is not completely clear, the index PRx [5] is
assumed to describe the response of small cerebral vessels
to spontaneous changes of arterial blood pressure (ABP) in
terms of changes of intracranial pressure (ICP), the so-
called cerebrovascular pressure reactivity (CVR) (Fig. 1).
The index Mx [4] describes the effect of spontaneous
changes in CPP (=ABP–ICP) on the transcranial Doppler
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assessed cerebral blood flow velocity (CBFV) in the middle
cerebral artery (MCA). Assuming the vessel diameter of
MCA to be almost constant in time [6], changes of CBFV
may be seen as a surrogate for changes of CBF. Therefore,
synchronous changes of CPP and CBFV may indicate a
lack of CA.
In former studies with traumatic brain injury (TBI)
patients, PRx coincided with classic measures of CA such
as the lower limit of autoregulation [7], and both PRx and
Mx were associated with clinical outcome [8–11]. In
patients with intracerebral hemorrhages a significant asso-
ciation between unfavourable outcome and increased PRx
[12] as well as increased Mx [13] was shown. However, in
a study with aneurysmal subarachnoidal hemorrhage
(SAH) patients, clinical outcome and PRx did not correlate
[14]. Recently, PRx has been used in the individual man-
agement of CPP in neurocritical care patients (so-called
‘optimal CPP’) [15–18].
Until now, little is known about the influence of
primary diseases, co-morbidities and other risk factors
such as age and neurosurgical interventions on the out-
come predictive value of autoregulatory indexes. PRx
and Mx describe different aspects of autoregulation, and
therefore, are likely to be differentially influenced by
such clinical characteristics. The primary aim of the
present study was to investigate the impact of selected
clinical characteristics on the association of both
autoregulation indexes Mx and PRx with 3-month clin-
ical outcome. The secondary aim was to confirm the
formerly reported association between autoregulation
indexes and clinical outcome [7–12] and investigate
whether this association was still valid in a cohort of
neurocritical care patients with very different types of
brain injury (TBI, haemorrhagic stroke, and others). Both
indexes were analysed in view of their suitability for
outcome prediction in different subgroups of patients
with specific clinical characteristics.
2 Materials and methods
2.1 Patient population
In a retrospective study, recorded signal data from 41
consecutive patients with severe cerebral diseases (age
18–77 years, mean 52 ± 17 years, 28 male/13 female)
who underwent multimodal monitoring between 2005 and
2009 were analyzed. Part of the study population had been
included in previous analyses focusing on different aspects
on CA monitoring [19]. Patients were treated in the Neu-
rocritical Care Unit of the Chemnitz Medical Centre. They
suffered either from TBI (N = 20) with subarachnoidal
hemorrhages (N = 7), intracerebral hemorrhages (N = 4)
and intracranial hematoma (N = 11), or from non-trau-
matic diseases (N = 21), i.e. aneurysmatic subarachnoidal
hemorrhages (N = 4), spontaneous intracerebral hemor-
rhages (N = 10), MCA infarction (N = 4), cerebral
venous sinus thrombosis, hypoxic encephalopathy, and
encephalitis. In 19 patients, hemicraniectomy was per-
formed. During time of data recording all patients were
sedated and mechanically ventilated with ventilator set-
tings fixed during recording time. Patients’ arterial partial
pressure of CO2 (PaCO2) ranged from 26 to 49 mmHg.
Patient management procedures included the maintenance
of CPP above 60 mmHg.
The study was approved by the Local Ethics Committee.
All signal monitoring was part of a clinical routine. The
retrospective data analysis did not require individual
consents.
2.2 Monitoring
A 2 MHz pulsed Doppler device (Multidop-P, DWL, Sip-
plingen, Germany) was used for assessment of transcranial
Doppler (TCD) signal. The envelope curve of CBFV in the
middle cerebral artery (MCA) was continuously monitored
Fig. 1 Physiologic model conception of PRx. If cerebrovascular
pressure reactivity (CVR) is intact (upper line), small cerebral vessels
dilate in response to decreasing ABP, resulting in an increased
cerebral blood volume. In regards to the pressure–volume curve of
brain [22–24], this causes an increase of ICP, i.e. ABP and ICP are
negatively correlated. If CVR is disturbed (lower line), ABP decrease
is passively followed by constriction of small vessels. This causes a
decrease of cerebral blood volume, and, therefore, causes a decrease
of ICP. ABP and ICP are positively correlated. Conversely, in the
case of increasing ABP, a negative correlation between ABP and ICP
is generally associated with intact CVR, while a positive correlation
between both signals indicates impaired CVR
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in the hemisphere ipsilateral to the brain lesion in most
cases. TCD signals were recorded during stable periods
free from nursing. ABP was measured with a standard
manometer line inserted into the radial artery. ICP was
measured using either implanted intraparenchymal or
intraventricular microsensor catheters (Raumedic GmbH,
Helmbrechts, Germany). ICP assessed by external ven-
tricular drain was not considered for recording.
2.3 Computer-assisted recording
Personal computers fitted with data acquisition systems
(Daq112B, Iotech, Inc., Cleveland, OH, USA) and software
developed in-house [20] were used for recording and
analyzing TCD, ABP and ICP signals and for calculation of
PRx and Mx (see below). For each recording time point,
signals were assessed over a 60 min period with a sampling
frequency of 25 Hz. If possible, recording was repeated at
days 2, 4, and 7. In total 130 recordings of 41 patients were
acquired.
2.4 Calculation of indexes PRx and Mx
PRx and Mx were calculated retrospectively. Initially, the
recorded signal data of CBFV, ICP and ABP was averaged
over 10-s intervals in order to erase oscillations from
mechanical ventilation and higher frequencies. Pearson’s
correlation coefficients were calculated from thirty con-
secutive average signals of ABP and ICP. The step length
was 10 s, i.e. correlations were performed over time peri-
ods of 5 min. This calculation was repeated every minute.
The computed correlation indices were averaged and
resulted in the pressure reactivity index PRx [5].
Mx was calculated completely analogous to PRx by
correlating averaged CBFV and CPP values instead of ABP
and ICP values [4].
Zero or negative values of these indexes indicate active
regulation of blood flow (Fig. 1) [4, 5], while positive
index values suggest impairment of flow regulation.
One PRx and one Mx value were calculated for each
signal recording (Fig. 2). For outcome analysis, these index
values were averaged over all recordings of each patient
thus resulting in one PRx and one Mx per patient.
2.5 Association with clinical outcome and statistics
The association of CA-indexes with 3-month clinical out-
come on the whole population including non-survivors was
assessed by:
1. The Pearson correlation after Mudholkar test [21] for
bivariate normal distribution between each index and
the mRS values, and
2. The area under the curve (AUC) of a ROC curve
analysis between index values and poor outcome
(score of mRS C 4). The significance of deviation of
ROC curve from 50 % line was assessed by Wil-
coxon–Mann–Whitney test. AUC connected with Mx
and PRx were compared using a method described by
DeLong et al. [22].
The association of CA-indexes with in-hospital mortality
was measured in terms of
1. A logistic regression between the CA-indexes and
mortality, and
2. The AUC of a ROC curve analysis between index
values and in-hospital mortality.
In both cases, the index was denoted as having predic-
tive value (of either poor 3-month outcome or in-hospital
mortality), if the corresponding statistical tests were sig-
nificant and AUC was above 0.7.
The weaker term ‘‘associated with outcome’’ denoted
significance of any of the performed statistical tests of
relationship between index and outcome.
In basic clinical data (Table 1), categorical comparison
was provided by Fisher’s exact test. Numerical character-
istics were compared by unpaired t test after Kolmogoroff–
Smirnoff test of normal distribution, association with out-
come was assessed by logistic regression analysis. Signif-
icance of shift of mRS scores in patients with low indexes
compared to those with high index values was assessed by
Mantel–Haenszel test.
3 Results
Baseline clinical characteristics of the studied patients are
shown in Table 1.
In-hospital mortality Six of the patients died in-hospital.
Reasons for death were increased ICP causing cessation of
cerebral blood flow (N = 2), decompensated hepatic
insufficiency (N = 2), and pulmonary embolism (N = 2).
On average, both PRx and Mx indexes were higher in the
Non-Survivors group than in the Survivors group, the dif-
ference being significant only in the case of PRx (Table 1).
Univariate logistic regression (ULR) analysis found alco-
hol abuse and PRx, but not Mx, as significant risk factors
for mortality (Table 1). ROC curve analyses between PRx
and mortality yielded 0.2 as the critical threshold (CT)
between low and high PRx; the AUC was 0.79. In addition,
the day-1 assessed PRx (PRx_day1) as well as the maxi-
mum of the two PRx values calculated on day 1 and on day
2 (PRx_max1&2) were tested for association with mor-
tality. Similar to (the averaged) PRx, both PRx_day1 and
PRx_max1&2 showed significant association with in-
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hospital mortality (ULR: p\ 0.05; PRx_day1:
AUC = 0.85; PRx_max1&2: AUC = 0.74). In case of
Mx, AUC was 0.70, and 0.38 was the CT. Using both CT,
the associations between high PRx and mortality as well as
high Mx and mortality were significant (p\ 0.05, Fisher’s
exact test).
Three-month clinical outcome In 36 patients, the
3-month clinical outcome in terms of scores of modified
Rankin Scale (mRS) could be assessed. ULR analysis
found Mx, but not PRx, as the only significant risk factors
for bad outcome (Table 1, col. 6). Significance of Mx
remained even if corrected to age (Table 1). A ROC curve
analysis yielded 0.2 as the CT of Mx for prediction of bad
outcome (mRS 4–6); AUC was 0.80. For PRx, the CT was
0.1 with AUC 0.64. High Mx ([0.2) was associated with
unfavourable outcome (p\ 0.005; Fisher’s exact test),
while high PRx ([0.1) was not. The patients with low Mx
showed a significant shift towards favourable outcome
scores (p\ 0.005; Mantel–Haenszel test) (Fig. 3), in con-
trast to low PRx where this shift effect was not significant.
Both PRx and Mx correlated significantly with mRS score
(PRx: r = 0.38, p\ 0.05; Mx: r = 0.48, p\ 0.005)
(Fig. 4; Table 2). Predictive value of autoregulation
indexes in clinical subgroups. PRx correlated significantly
with mRS in TBI patients but not in patients with non-
traumatic diseases (Table 2). Mx behaved conversely. Both
PRx and Mx correlated with mRS in patients with hemi-
craniectomy (N = 19). Neither PRx nor Mx correlated
with mRS in patients without hemicraniectomy, in older
patients ([60 years; N = 14) and in patients with diabetes
Fig. 2 Signal recording of a 71-year-old patient with hemorrhagic
stroke, heart failure, and a 3-month outcome mRS score of 4. CBFV,
ABP and ICP have been recorded for 3450 s. CPP was calculated by
ABP–ICP. In the lower channel, signal correlation coefficients are
indicated either by circles (between CBFV and CPP, for Mx
calculation) or by squares (between ABP and ICP, for PRx
calculation) and moving average curves of five consecutive correla-
tion coefficients are drawn. The signals CBFV and CPP showed
strictly parallel fluctuations, while signal changes of ABP and ICP
were clearly opposed. Accordingly, the indexes strongly differed: Mx
was 0.31, indicating impaired CA, while PRx was -0.77, indicating
intact cerebrovascular reactivity. The moderately severe outcome
(mRS score = 4) better fits to the Mx value. ABP arterial blood
pressure, CA cerebral autoregulation, CPP cerebral perfusion pres-
sure, CBFV cerebral blood flow velocity, ICP intracranial pressure,
mRS modified Rankin Scale
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mellitus (N = 15). In patients with congestive heart failure
(NYHA state I or higher; N = 18), Mx but not PRx cor-
related with mRS (Fig. 2). AUC of Mx ranged from 0.71
(in patients below 60 years) to 0.92, AUC of PRx ranged
from 0.64 (in total population) to 0.89 (Table 2). Mx and
PRx did not significantly correlate in patients above
60 years and in heart failure patients. Compared to Mx and
PPx, non-averaged index values such as e.g. PRx_day1
Table 1 Basic clinical data and association with in-hospital mortality and 3-month outcome
Characteristics All patients
N = 41
In-hospital mortality Three-month clinical outcome (mRS)
Survival; death
N = 35; 6
Logistic regression
OR; 95 % CI
Good; poor outcome
N = 14; 22
Logistic regression
OR; 95 % CI
Age 52 ± 16 51 ± 16; 60 ± 10 1.04; 0.98–1.11 46.9 ± 16.0; 56.6 ± 15.6 1.04; 0.99–1.09
Age (with PRx) 1.03; 0.98–1.08
Age (with Mx) 1.02; 0.97–1.08
Female 13 12; 1 2.6; 0.26–26.40 4; 9 0.7; 0.16–3.1
Hemicraniectomy 19 18; 1 5.3; 0.53–53.0 7; 12 1.2; 0.30–4.78
TBI 20 16; 4 1.45; 0.42–4.95 6; 14 1.32; 0.97–1.80
Heart failure 18 17; 1 4.72; 0.47–47.23 6; 12 0.75; 0.19–3.00
Diabetes mellitus II 15 12; 3 0.52; 0.09–3.12 5; 10 0.67; 0.16–3.00
Alcohol abuse 9 4; 5*** 38.8; 3.36–447*** 2; 7 2.25; 0.37–13.8
PaCO2 (mmHg) 37.0 ± 4.7 37.1 ± 5.0; 36.7 ± 2.1 0.98; 0.80–1.21 37.2 ± 6.4; 37.5 ± 3.7 1.02; 0.88–1.18
ABP (mmHg) 89 ± 11.2 90 ± 11.3; 85 ± 9.7 0.96; 0.89–1.05 91.0 ± 12.7; 86.0 ± 10.7 0.96; 0.90–1.02
ICP (mmHg) 12 ± 9.3 11 ± 3.8; 20 ± 20.6 1.11; 0.96–1.28 10.7 ± 4.3; 13.1 ± 12.4 1.03; 0.93–1.14
PRx 0.12 ± 0.27 0.07 ± 0.22; 0.41 ± 0.33*** 1.71; 1.09–2.69* 0.04 ± 0.24; 0.22 ± 0.28 1.32; 0.97–1.80
PRx (with age) 1.26; 0.92–1.72
Mx 0.09 ± 0.26 0.06 ± 0.23; 0.28 ± 0.40 1.40; 0.89–2.18 -0.07 ± 0.21; 0.21 ± 0.27*** 1.64; 1.13–2.37**
Mx (with age) 1.57; 1.07–2.28*
Clinical data refer to the complete patient group (col. 2), as well as to the subgroups of patients specified by in-hospital mortality (col. 3) and
3-month outcome (col. 5). Data is in terms of occurrence or mean value ± SD. Impact on outcome was assessed by Fisher’s exact test, unpaired
t test (cols. 3, 5), or univariate logistic regression analysis (cols. 4, 6). In addition, impact of both Mx and PRx on 3-month outcome was assessed
age-corrected by bivariate (PRx and Age, as well as Mx and Age) logistic regression. Alcohol abuse and high PRx, but not Mx, were significant
risk factors for mortality, while Mx, but not PRx, was a significant predictor of poor outcome. High PRx and alcohol abuse were not associated
(p[ 0.2, Fisher’s exact test)
OR odds ratio, mRS modified outcome scale, mRS C 4 denotes poor outcome
Significance levels: * p\ 0.05; ** p\ 0.01; *** p\ 0.005; *** p\ 0.001
Fig. 3 Three-month outcome in
patients with high Mx and with
low Mx. In patients with low
Mx (Mx\ 0.2; N = 23) the
distribution of mRS scores
(upper bar) was shifted towards
lower scores (indicating better
outcome) if compared to the
mRS scores of the patients with
high Mx (Mx C 0.2; N = 13;
lower bar). In seven patients
mRS was either 2 or 1, in all of
them Mx was low. The
difference between outcome
distributions of both groups was
significant (p\ 0.005; Mantel–
Haenszel test). mRS modified
Rankin Scale, 0 no symptoms–6
death)
J Clin Monit Comput (2016) 30:367–375 371
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showed clearly lower association to 3-month outcome and
were not presented here. Detailed results are provided in
Table 2.
4 Discussion
In this study, CA related indexes were applied to patients
with both traumatic and non-traumatic diseases. Despite
this heterogeneity of diseases, both PRx and Mx were
significantly associated with clinical outcome. CA is a
central mechanism in brain and its failure might be a
pathology in itself within any causing disease. However,
some of our results suggested an impact of the underlying
diseases. In particular, PRx fitted better to TBI patients,
while Mx had a stronger correlation with outcome in
patients with non-traumatic diseases.
4.1 PRx and Mx focus on different aspects
of autoregulation
Hyperventilation, heart failure, and hemicraniectomy clearly
influenced the predictive value of PRx and Mx. In hyper-
ventilated patients, the cerebral vasoconstriction effect of
low PaCO2 may have impaired the predictive value of PRx.
In heart failure, insufficient cardiac output and autoregula-
tory failure was detected by Mx, which assesses blood flow
dynamics, but was not detected by PRx. This may explain
why PRx and Mx did not correlate in patients with heart
failure and why only Mx was predictive in these patients. The
observation of improvement in PRx in hemicraniectomy
patients confirmed [23] and contradicted [24] former reports.
The strength of ICP reactions to ABP changes depends on the
current slope of the intracranial pressure–volume curve
(Fig. 1). Therefore, PRx is influenced by cerebral compli-
ance (CC), which is the reciprocal of this slope [26, 27].
While CC may vary in patients without hemicraniectomy, it
may be assumed that this co-factor of PRx remains similar in
all patients with hemicraniectomy. This might explain why
PRx was an improved predictor of mRS in patients with
hemicraniectomy and failed in patients without. However,
only six of the 19 patients without hemicraniectomy suffered
from TBI, which suggests a contribution of non-traumatic
diseases to the failure of PRx in this group. Therefore, these
results do not contradict a previously reported significant
association of PRx with outcome in purely TBI patient
groups without hemicraniectomy [8, 11]. The differences of
predictive values between patients with and without hemi-
craniectomy were less pronounced in Mx. The confounding
effect of CC on PRx was previously used to explain dis-
crepancies between Mx and PRx during increase of ICP [28].
4.2 Role of early versus late outcome parameters
Mx was a better predictor of 3-month mRS than PRx, while
PRx was superior to Mx in predicting the early in-hospital
mortality. The reason for this imbalance is unclear. Similar
observations were made in recent studies with PRx and Mx
in TBI patients only [11, 28]. It might be that to some
extent disturbance of CVR (assessed by PRx) is a priori
associated with affected brain viability, while impaired
CBF (assessed by Mx) may cause secondary damage,
which affects outcome but predominantly may not be
lethal. Following this hypothesis, Mx-controlled manage-
ment of CPP would appear particularly promising. How-
ever, due to the problems with long-term TCD insonation,
clinical interventions have been focusing so far on the
setting of PRx-optimized CPP [15–18].
4.3 Limitations
Our study included a small number of patients. Confirma-
tion of the results using larger populations is necessary. For
sub-group analyses, ‘clinical characteristics’ were defined
as cardiovascular risk factors that had the potential to affect
patient outcome. However, adequate incidence of each risk
factor was essential for statistical analysis. For this reason,
not all cardiovascular risk factors could be analysed e.g.
‘alcohol abuse’ was analysed as there were nine reported
events; ‘smoking’ could not be analysed because it was not
consistently reported. In our hospital, we tested CA but did
not continuously monitor it. Therefore, additional infor-
mation such as the time duration of increasing indexes was
not available. Recently this parameter was shown to cor-
relate with 3-month outcome [16]. In our study we used
Fig. 4 PRx and Mx plotted versus modified Rankin Scale (mRS). In
the subgroup of 36 patients with known 3-month outcome, higher
index values corresponded to poorer outcome. mRS scores were
significantly correlated with PRx (r = 0.38, p\ 0.05), and even
stronger correlated with Mx (r = 0.48, p\ 0.05)
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averaged values of Mx and PRx and correlated these values
with outcome. A general drawback of this method is that it
neglects time-related changes in autoregulation and in
some cases may lead to the ‘averaging out’ of occasional
extreme index values. This is clearly a weakness of this
kind of approach. On the other hand, averaged PRx or
Mx, in previous studies [9–12] were found to be inde-
pendent predictors of outcome, therefore, in the present
study we relied on this method. Moreover, association of
these averaged indexes with outcome was confirmed by
our own results. In cases of in-hospital mortality we also
studied non-averaged PRx values, because averaging the
index over several days for prediction of a possible sud-
den event does not seem to be clinically useful. However,
we found an association of these parameters with mor-
tality as well.
In our study, independence of autoregulation indexes
from other clinical parameters could not be stated due to a
limited number of events, thus limiting the application of
multivariate logistic regression [29]. In our study, 14
patients had a favourable outcome. Therefore, even if re-
laxing the commonly used rule of ten events per indepen-
dent variable [29], we could not consider more than two
risk factors for logistic regression with the target variable
‘good/bad outcome’. However, we investigated patients’
age as joined risk factor. Another natural risk factor, the
Glasgow Coma Score on admission was not sufficiently
documented for evaluation.
Deviation of CPP from CPPopt was formerly reported to
be associated with bad outcome [15, 16]. However, we
could not include this parameter in our analysis. Our
recordings at each time point were limited to 1-h periods.
Table 2 Association of Mx and PRx with 3-month outcome in various patient subgroups
Subgroup specification Correlations
Number of patients Pearson correlation coefficient; AUC of ROC curve; critical threshold
N; N(mRS) mRS–Mx mRS–PRx Mx–PRx
41; 36 0.48***; 0.80***; 0.20 0.38*; 0.64; 0.10 0.55***
Type of disease
TBI 20; 16 0.49 0.63**; 0.89**; -0.06 0.56**
Non-TBI 21; 20 0.49*; 0.79*,#; 0.14 0.09 0.55**
Age
[60 years 14; 13 0.18 0.44 0.06
\60 years 27; 23 0.43*; 0.71 0.30 0.62***
PaCO2 (mmHg)
26–40 31; 26 0.55***; 0.77*; 0.14, 0.59 0.31 0.57***
30–49 39; 34 0.59***; 0.82***; 0.20 0.47**; 0.69 0.58***
35–49 27; 24 0.68***; 0.92***; 0.00 0.57***; 0.76 0.68***
Heart failure
Yes 18; 17 0.69***; 0.92***; 0.00 0.34 0.37
No 23; 19 0.38 0.43 0.63***
Hemicraniectomy
Yes 19; 17 0.69***; 0.87*; 0.26 0.73***; 0.89**; 0.07 0.58**
No 22; 19 0.41 0.10 0.53**
Diabetes mellitus II
Yes 15; 15 0.20 0.41 0.57*
No 26; 21 0.68***; 0.87***; 0.00 0.36 0.57***
In the complete patient population and in various subgroups correlations were calculated between mRS and Mx and PRx as well as between PRx
and Mx. If the index correlated with mRS and number of cases was at least 15, AUC with critical threshold, sensitivity and specificity of index
for prediction of poor outcome (mRS C 4) were presented. PRx and Mx mutually correlated except in patients above 60 years and in patients
with heart failure. Mx did not correlate with mRS in patients above 60, in patients with diabetes, and in patients without heart failure. PRx
correlated with mRS in TBI patients. PRx did not correlate with mRS in non-traumatic patients, in age-specified subgroups, and in the heart
failure and diabetes related subgroups. In patients with hemicraniectomy, both PRx and Mx correlated with mRS, but did not in patients without
hemicraniectomy. Predictive value of indexes was higher in normal PaCO2 range ([35 mmHg) than in patients with low PaCO2 (26–35 mmHg).
Although AUC clearly differed between Mx and PRx, the difference was significant only in the group of non-traumatic patients
AUC area under the curve; correlation: for simplicity denotes a significant correlation, mRS modified Rankin Scale, N population size; N(mRS)
number of patients with known 3-month mRS score
Significance levels: * p\ 0.05; ** p\ 0.01; *** p\ 0.005; *** p\ 0.001; # significance of Mx–PRx difference in AUC (p\ 0.05)
J Clin Monit Comput (2016) 30:367–375 373
123
This duration was too short for calculating CPPopt.
Although being visibly different, comparison of AUC for
3-month outcome showed a significant difference between
PRx and Mx only in the group non-traumatic patients. This
might be caused by the small sizes of investigated sub-
groups. We had access to a detailed mRS score in only 36
patients. This produced a predominance of in-hospital fatal
outcomes; all fatalities were reported. In contrast to other
studies [11, 25], ICP was not a risk factor of poor outcome.
However, ICP was elevated ([20 mmHg) in only one of
our patients.
The primary cerebral disease state directly caused death
in only two of the study patients. The question may arise
whether there is any logic in considering brain-derived
indexes such as PRx and Mx in patients who died from
multi-organ failure after hepatic insufficiency or pul-
monary embolism. However, reasons for death are complex
and multi-factorial. In our study, we found a significant
association between CA-indexes and death, but we could
not provide evidence of causality.
5 Summary
Both PRx and Mx were significantly associated with in-
hospital mortality and 3-month clinical outcome. PRx was
more strongly associated with in-hospital mortality than
Mx, while Mx was superior in prediction of functional
outcome after 3 months. PRx was a predictor of 3-month
outcome in TBI patients, but was not suitable for non-
traumatic patients or patients with heart failure. Mx was a
predictor of 3-month outcome in non-traumatic patients
and in patients with heart failure. Both indexes were suit-
able for patients with hemicraniectomy. In patients older
than 60 years and in patients with diabetes, neither PRx nor
Mx was associated with outcome. Predictive value PRx
was best if PaCO2 was kept above 35 mmHg. If PRx was
applied to TBI patients and Mx to patients with non-trau-
matic diseases, the overall strongest correlations to out-
come were observed.
6 Conclusion
Outcome predictive values of PRx and Mx depend on
patient characteristics. Further studies with larger popula-
tions should be performed on this subject to allow rec-
ommendations for an index-specific clinical use.
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